Coultreon Biopharma

Coultreon Biopharma is a clinical-stage biotechnology company focused on developing life-altering therapies for patients with rare and ultra-rare endocrine and metabolic diseases. The company's lead candidate, CLT-001, is a recombinant human insulin-like growth factor-1 (rhIGF-1) complexed with recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3). This modality, known as mecasermin rinfabate, is designed to treat severe insulin resistance syndromes such as Donohue Syndrome and Rabson-Mendenhall Syndrome. By providing a stabilized form of IGF-1, the therapy aims to bypass defective insulin signaling pathways to regulate glucose metabolism. Coultreon was established by a leadership team with a proven track record in rare disease drug development, including former executives from Horizon Therapeutics. The company is supported by a significant Series A investment from leading life science venture capital firms.